Exelixis Inc (EXEL) 銘柄情報

EXEL, new 52 week high

EXEL announces another $500 million in shares repurchasing, expected to be completed by year end.

https://finance.yahoo.com/news/exelixis-announces-newly-authorized-500-220500850.html

After more than five years of follow-up, CABOMETYX in combination with Opdivo continued to show survival benefit compared with sunitinib

in Patients with Advanced Kidney Cancer

https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-final-five-year-follow-results-checkmate-9er

EXEL massively beats on earnings and raises guidance. The stock is up $1 after hours and it sure looks like it will close over $30 tomorrow.

https://finance.yahoo.com/news/exelixis-announces-third-quarter-2024-200500722.html

Good I can get back in!

EXEL under $30

EXEL wins the patent dispute with MSN laboratories so their patent protection is secure through 2030. The MSN patent lawsuit has been a weight on EXEL's stock price. Could see continued upward price movement this week and beyond.

https://finance.yahoo.com/news/exelixis-announces-second-patent-litigation-175700922.html

EXEL is over $28/share today. It has been a long, long wait for such a rise, since Jan 2018.

EXEL more upside possible

Great earnings report today! Things are finally on the upswing!!!

Great earnings report today! Things are finally on the upswing!!!

Wow glad we held this! Wealth$$$$$

Analyst Ratings For Exelixis
11/3/21 12:43 PM ET (Benzinga)Print
Over the past 3 months, 5 analysts have published their opinion on Exelixis (NASDAQ:EXEL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

BullishSomewhat BullishIndifferentSomewhat BearishBearish

Total Ratings32000

Last 30D11000

1M Ago11000

2M Ago10000

3M Ago00000

These 5 analysts have an average price target of $35.2 versus the current price of Exelixis at $19.505, implying upside.

Below is a summary of how these 5 analysts rated Exelixis over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the move negative analysts are on the stock

This current average has decreased by 14.15% from the previous average price target of $41.0.

What Are Analyst Ratings?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

Latest Ratings for EXEL DateFirmActionFromTo

Nov 2021RBC CapitalMaintainsOutperform Nov 2021HC Wainwright & Co.MaintainsBuy Nov 2021OppenheimerMaintainsOutperform

Exel looking good

This is a winner! $$$$

News; $EXEL Exelixis to Host Investor Briefing to Discuss Data Presented at the European Society for Medical Oncology Virtual Congress 2020

- Online event will be accessible at www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced it will host an investor briefing to discuss data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The online-only event will be held following ...

Got this from EXEL - Exelixis to Host Investor Briefing to Discuss Data Presented at the European Society for Medical Oncology Virtual Congress 2020

Just In: $EXEL Got $5,000? 3 Surefire Stocks to Buy Ahead of the Next Market Crash

When the S&P 500 lost 4.3% in two days last week, some of our bull market enthusiasm may have faded. And many of us were probably thinking back to the March market crash . Are we prepared for the next one? It may not be right around the corner, but it's never too early to prepare for oppo...

Find out more EXEL - Got $5,000? 3 Surefire Stocks to Buy Ahead of the Next Market Crash

EXEL +1.71 really hard move up in final minutes don't see any news?

Anyone know why?

Bueller?


It about freaking time! My question is more along the lines of "why did EXEL drift down so much the past month or two?"

a Lot of volume on those closing buys

EXEL +1.71 really hard move up in final minutes don't see any news?

Anyone know why?

Bueller?

Could be a better play here than acad, playing both for long term $$

When cabo an cobi move to the next phase! $$$$$

Mr. Crumb what is the next catalyst for EXEL? You still thinking $50?

Might be a sell at 30+ here, will monitor news

Told everyone 2 yrs ago to hold an accumulate. This is the next acad! Yes 50+ is a great target. $$$

Going to $50!!!

That is possible with a buyout.

Going to $50!!!

I see Motley Fool recommending this stock, but I don't see why. What I see is a stock that can't break through it's resistance and earnings are falling.
What am I missing here?

An opportunity to add is here folks. $$$$

Going to buy more. Longvan strong for buyout in the 30’s. This is a copycat of aria! $$$$

Buy these up people, buyout coming!

All that means is this company will be sold at some point! Should be in excess of the 35 area

Approval of the proposal of Exelixis’ Board of Directors to amend Exelixis’ Amended and Restated Certificate of Incorporation to declassify the Board of Directors to provide for annual elections by the 2020 Annual Meeting of Stockholders.
What that mean?
If you can explain
Appreciate it

Big money made here! Holding a core in the event of a 30+ buyout! $$$$$

Congrats to all who bought more or consolidated around the 14 area. Wealth! $$$$

They approved 5 or 6 on the 10th...and previous days..jus sayin...who knows huh in this day an age

Be careful. Powers that be take it lower just before Options expiration then take it back up.

Hhhmmmm, time to double up

Yes pdufa still on board for January

Nice pop today, back to the 20+ it should go

I own a few hundred shares, is their Jan 14th 2019 pdufa still on
or did the news come early? I just read an article the stated just that but there is no date when the article was written.

ESMO underway and EXEL has already presented BIG results from two trials. Share price will be much higher by the time ESMO ends and then even higher after Nov 1st earnings which will be another huge EPS beat (given the revenue growth; royalties coming in and milestone payments during the qtr).

Personally added a bunch more during the big negative days this week as well a little more on Friday. Couldn't be more happier given the bright future ahead for EXEL in 2019. Should be on path to set new 52 week high after more positive news in 2018 and then the BIG start in 2019 with the HCC approval and another big Qtr'ly release in early Feb. Lastly, remember there are another 70+ trials ongoing (mono and combo) which will have output in 2019 as well.

Still long here. Patience as usual. $$$

Up 8% to 22.15 on stellar earnings. Should reach $25 very quickly and then tutes jump in and we see new 52 week high of $32.5 plus

Killer earnings means $25 plus here we come! Glad I jumped in heavy and added a bunch more at $20.50

Looks like a great entry point at $20.50 . Jumped in with both feet as this company should be much higher in share price. Looking forward to earnings and future HCC news!

https://www.healio.com/endocrinology/adrenal/news/online/%7B3a878803-7fd1-417e-9946-69ac07c76b14%7D/cancer-drug-may-benefit-patients-with-metastatic-pheochromocytoma-paraganglioma

People need to start reading and sharing these posts

https://www.healio.com/endocrinology/adrenal/news/online/%7B3a878803-7fd1-417e-9946-69ac07c76b14%7D/cancer-drug-may-benefit-patients-with-metastatic-pheochromocytoma-paraganglioma

https://seekingalpha.com/article/4175380-may-best-time-pick-exelixis-2018

https://www.streetinsider.com/Analyst+Comments/Oppenheimer+Reiterates+Outperform+on+Exelixis+%28EXEL%29/14207378.html